First Turn Management LLC Has $12.37 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

First Turn Management LLC trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 37.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,942 shares of the company’s stock after selling 41,280 shares during the period. First Turn Management LLC owned approximately 0.24% of Krystal Biotech worth $12,367,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Sei Investments Co. raised its holdings in Krystal Biotech by 128.3% during the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after buying an additional 18,968 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in Krystal Biotech by 18.5% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 7,307 shares of the company’s stock worth $1,300,000 after buying an additional 1,140 shares during the period. CANADA LIFE ASSURANCE Co raised its holdings in Krystal Biotech by 80.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 3,128 shares of the company’s stock worth $557,000 after buying an additional 1,397 shares during the period. Capital World Investors acquired a new stake in Krystal Biotech during the 1st quarter worth approximately $17,285,000. Finally, Affinity Asset Advisors LLC raised its holdings in Krystal Biotech by 7.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 26,746 shares of the company’s stock worth $4,759,000 after buying an additional 1,746 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Price Performance

KRYS stock opened at $175.64 on Tuesday. The company has a fifty day moving average price of $180.83 and a two-hundred day moving average price of $181.79. Krystal Biotech, Inc. has a one year low of $99.00 and a one year high of $219.34. The stock has a market cap of $5.05 billion, a price-to-earnings ratio of 99.23 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. During the same period in the previous year, the business posted ($0.67) earnings per share. The company’s revenue for the quarter was up 879.9% compared to the same quarter last year. Research analysts anticipate that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on KRYS. Citigroup raised their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Chardan Capital raised their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Stifel Nicolaus raised their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $197.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).